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Abstract
Background: Immunological alterations are implicated in the increased prevalence of high-grade
squamous intraepithelial lesions (HG-SIL) and persistent human papillomavirus (HPV) infection.
This study evaluated the expression of CD4, CD8, CD25 (IL-2Rα) and CD28 antigens from SIL
biopsies, stratified by HIV status and HPV-type. Biopsies specimens from 82 (35 HIV+) women with
a normal cervix, low-grade (LG-SIL) or high-grade lesions (HG-SIL) were studied. CD molecule
expression was evaluated by immunohistochemistry and HPV detection/typing performed using
PCR techniques.
Results:  CD4 stromal staining was increased in patients with HPV18. Women with HPV16
infection showed decreased: a) CD8 and CD25 stromal staining, b) CD25 staining in LG-SIL
epithelium and in HG-SIL stroma. In HIV- women samples, CD28 epithelial staining and CD8
stromal staining surrounding metaplastic epithelium were less intense and even absent, as
compared to HIV+ women. Both epithelial and stromal CD8 staining was more intense in the HG-
SIL/HIV+ group than in the HG-SIL/HIV- group. Positive correlations were observed between CD4/
CD25, CD4/CD28 and CD25/CD28 in the stroma and CD25/CD28 in the epithelium.
Conclusion: HIV status and HPV-type may influence the lymphomononuclear cell profile present
in the spectrum of cervical lesions. The knowledge of the infiltrating cell profile in cervical tumours
may help the development of specific anti-tumoural strategies.
Introduction
Human Immunodeficiency Virus (HIV)-infected women
have a high prevalence of persistent human papilllomavi-
rus (HPV) co-infection and also of squamous intraepithe-
lial lesions (SIL) [1]. The progression from HIV infection
status to acquired immune deficiency syndrome is
marked by a decreasing CD4 count and increasing HIV
viral load, both of which have been associated with the
HPV persistence and SIL severity [1,2].
HPV may evade immune surveillance by shifting Th cell
polarization, down-regulating the expression of Major
Histocompatibility Complex (MHC) class I molecules
and reducing the function of intraepithelial antigen-pre-
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senting cells, which may cause a lack of Th1 polarization
from the beginning of HPV infection. This causes a shift to
the production of IL-4, IL-6 and/or the immunosuppres-
sive cytokine IL-10 [3,4]. Similarly, the progression from
HIV infection to AIDS has been associated with the polar-
ization to the Th2 cytokine profile in cervicovaginal secre-
tion[5] which might contribute to the persistence of HPV
infection [6].
In the general population, tumour infiltrating lym-
phocytes in cervical cancer have been associated with a
depressed function of cytotoxic T cells [7,8]; a down-regu-
lation of CD25 (α chain of the IL-2 receptor-IL-2Rα) acti-
vated cells [9] and a decreased proportion of CD4+ T cells
with a reversed CD4/CD8 ratio [10]. In HIV-infected
women, little information is available regarding the infil-
trating T cell phenotypes; however, deregulation of
peripheral blood CD4/CD8 T cell function is progres-
sively impaired [11] with hyporesponsiveness of T CD8
cells to activation by the co-stimulatory CD28 and CD40L
molecules [12]. To date it is not clear whether these
defects in HIV-infected women also occur in the cervicov-
aginal milieu and whether these might be implicated in
the increased prevalence of HG-SIL.
The interaction of the T-cell receptor with the MHC mole-
cule is considered to be the first signal for T cell activation.
CD4 and CD8 antigens, observed on the surface of T cells,
are co-receptors that bind to non-polymorphic regions of
MHC class II and class I molecules, respectively and trans-
duce signals that initiate T cell activation. The second sig-
nal for T cells stimulation is provided by the interaction of
co-stimulator molecules, including CD28 antigen on T
cells and CD80/CD86 on the surface of activated antigen
presenting cells. Activation of T cells by antigens and co-
stimulators stimulate the production and secretion of IL-
2, which in turn induces the production of the IL-2 recep-
tor (IL-2R). The IL-2R is formed by three non-covalently
associated protein called a (IL-2Ra), b (IL-2b) and g (IL-
2g) chains. The activation of T cells by antigens, co-stimu-
lators and IL-2 leads the expression of IL-2a (CD25) [13].
To determine the possible associations between CD4,
CD8, CD25 and CD28 antigens expression in several
stages of cervical cancer development, we assessed the
expression of these molecules in cervical biopsies strati-
fied according to the severity of the lesion and HPV type
detected (HPV16 and 18).
Materials and methods
Sample selection
The study was conducted retrospectively on 82 (47 HIV-
negative and 35 HIV-positive), non-pregnant, non-lactat-
ing, premenopausal women, which were recruited
sequentially according to their arrival at the outpatient
clinic. They were colposcopically and cytologically
screened, selected for cause, i.e., the presence or absence
of HPV and cervical intraepithelial lesions. Median age
was 36 years (range 19  50) for HIV-negative women and
29 years (range 1947) for HIV-positive women. These
women were enrolled at several Gynaecological Reference
Services in the State of São Paulo, Brazil, from 1996 to
2001 and the study protocol was approved by the institu-
tional Ethics Committee on human experimentation.
Colposcopies were performed for routine in all women
and when indicated, the same physician performed colpo-
scopically directed cervical biopsies or conization loop
excision. Cervical fragments were fixed with formalin and
then slides were stained with haematoxylin-eosin (Sigma,
St. Louis, MO, USA) and histologically evaluated by two
experienced histopathologists, who also provided scoring
representing the sum of intensity and distribution of
staining in fields, in a double-blinded protocol. Thin 5
μm sections were cut, placed on organosilane-pretreated
slides and submitted to immunohistochemical assays. An
additional 10 μm section was used for DNA extraction
and HPV typing.
Cervical biopsies were selected from HIV-negative or HIV-
positive women and they were stratified into 3 groups:
normal (no evidence of SIL or HPV DNA), low-grade SIL
(cervical intraepithelial neoplasia I) and high-grade SIL
(cervical intraepithelial neoplasia II-III and in situ carci-
noma).
Immunohistochemistry
Serial sections (34 μm) obtained from paraffin-embedded
blocks, cut and mounted on APTS (3-aminopropyltri-
ethoxy-silane, Sigma, Saint Louis, USA)-pre-treated glass
slides were dried by the method of Alves et al. [14]. To pre-
vent cross-reaction with endogenous peroxidase, the
slides were treated with 3% H2O2 for 20 min and then
incubated overnight at room temperature with the follow-
ing primary antibodies at the following dilutions: CD4
(mouse monoclonal, clone 1F6, IgG1  NovoCastra, New-
Castle upon Tyne, UK) 1:80; CD8 (mouse monoclonal,
clone 4B1L, IgG2b  NovoCastra), 1:200; CD25 (mouse
monoclonal, clone 4C9, IgG2b  NovoCastra) 1:300;
CD28 (goat policlonal, clone N20, SC 1625  Santa Cruz
Biotechnology, Santa Cruz, CA, USA), 1:300. Sections of
human tonsils were used as positive controls, and a nega-
tive control to detect background staining was performed
by omitting the primary antibody. Isotype specificity for
tonsil sections was confirmed by comparison of staining
with irrelevant antibodies of the same isotype as the pri-
mary antibody. A control incubation to detect back-
ground staining was performed omitting the primary
antibody.
After incubation with the primary antibodies, immu-
noperoxidase staining was performed using a universal
biotinylated secondary antibody mixed with a preformedInfectious Agents and Cancer 2009, 4:11 http://www.infectagentscancer.com/content/4/1/11
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avidin and biotinylated horseradish peroxidase macro-
molecular complex (Novostain super ABC kit-NovoCas-
tra), diluted 1:200 for CD4, CD8, CD25 and a different
biotinylated secondary antibody (Vector, BA 5000, anti-
goat IgG  Burlingame, CA, USA) diluted 1:200 for CD28.
Slides were alternately washed 3 times with PBS and TBST
(Tris-buffered saline; 0.05 M Tris, pH 7.4, containing
0.3% Tween 20) and diaminobenzidine (0.5 mg/mL)
(Sigma) was used as chromogen. Slides were then sequen-
tially counter-stained with haematoxylin without acid for
30 sec, washed in tap water, stained blue with ammonia-
cal water for 20 sec and exhaustively rinsed with tap water.
Finally, slides were dehydrated and mounted for light
microscopy evaluation at 400× magnification using an
eyepiece graticule connected to an objective lens, as
detailed elsewhere [15].
A minimum of 10 fields (total area equivalent to 0.75
mm2) was assessed per case. The expression of CD anti-
gens was evaluated using a previously described semi-
quantitative method [16]. A total score representing the
sum of intensity and distribution of staining in fields pre-
senting dysplastic epithelium and in the respective subep-
ithelial stroma was assigned to each case. The intensity of
cellular staining in epithelium and stroma was scored as:
(0) no staining, (1) weak; (2) moderate; and (3) intense.
Staining in the epithelium was scored as follows: (0),
patchy basal; (1), diffuse basal; (2), diffuse full-thickness;
(3), patchy and diffuse full-thickness positivity. Staining
distribution in stroma was categorised as: (1), patchy sub-
epithelial; (2) diffuse full-extent; (3) patchy and diffuse
full-extent positivity. Only sections showing epithelial
and stromal tissue were considered for the analysis.
HPV identification and typing
HPV DNA obtained from paraffin blocks [17] was ampli-
fied by PCR using 12.5 pmoles of dNTP, 25 pmoles of
each primer, 1.5 U Taq DNA polymerase (Gibco, USA), 5
μL of 10× enzyme buffer, 20 μg of genomic DNA (50 ng)
and distilled deionised H2O to complete a total volume of
50 μL. The mixture was processed in a thermocycler appa-
ratus (MJ Research, MA, USA) under the following cycling
conditions: 1 cycle at 95°C for 5 min, 30 cycles at 95°C
for 30 sec, at 55°C for 30 sec and at 72°C for 1 min and
finally 1 cycle at 72°C for 10 min and then at 4°C indefi-
nitely.
Since formalin may degrade DNA, producing DNA frag-
ments of different length, several pairs of primers were
used. Primers GP5+ and GP6+ [18], which amplify small
DNA fragments and primers MY09 and MY11 [19], which
amplify longer DNA fragments, were used for generic HPV
amplification. Since HPV16 and HPV18 are the types
most frequently associated with cervical neoplasia, 2 sets
of specific primers were used to detect the E7 gene, one
from HPV16 (HPV16E7.667 and HPV16E7.774 primers)
and another one from HPV18 (HPV18E7.696 and
HPV18E7.799 primers) [20]. All DNAs were amplified
with these 4 sets of primers together with a set of primers
for a housekeeping gene (globin) [21] as an internal con-
trol of amplification. Amplified DNA was applied to a
10% polyacrylamide gel, electrophoresed at 200 volts for
1.45 h and stained with AgNO3 by the method of Sangui-
netti et al [22]. It is important to note that the absence of
HPV16 or HPV18 did not exclude the presence of HPV
types other than 16 or 18, which could be identified if spe-
cific primers for them were used. Only unambiguous
amplifications were considered as positive. Lack of ampli-
fication with these primers or ambiguous amplifications
after several repetitions were assigned as other HPV types.
Statistical Analysis
According to the distribution of the variables and the
number of groups compared, statistical analysis was per-
formed using the unpaired t, Mann-Whitney and Kruskall-
Wallis tests. The Spearman test (r) was used to calculate
correlations. P values were two-sided and the level of sig-
nificance was set at ≤ 0.05. All data were analysed using
the Instat Mac 2.01 software (GraphPad software, CA,
USA).
Results
Patient data
Among the 47 HIV-negative women, 4 exhibited no cervi-
cal lesions and 43 presented SIL (13 LG-SIL and 30 HG-
SIL). Among 35 women presenting HIV-infection, 5
exhibited no cervical lesions and 30 women presented SIL
(21 LG-SIL and 9 HG-SIL). According to CD4 counts, 9
HIV-positive women presented CD4 counts > 500 cells/μL
and 26 of them CD4 counts < 500 cells/μL. The median
peripheral CD4 T-cell count of the group presenting with
both SIL and HIV infection was 360 cells/μL. Patient data
stratified by lesion severity (LG-SIL, HG-SIL), HIV status
and HPV type are shown in Table 1.
CD4 and CD8 staining
CD4 and CD8 staining was observed in cells presenting
the morphology of lymphomononuclear cells. CD4 stain-
ing was observed throughout the squamous epithelium,
and remarkably more intense in the stroma under the
transformation zone and surrounding endocervical
glands, especially near inflammatory areas. CD4 stromal
staining was increased, particularly in specimens present-
ing HPV18, when compared with those without HPV18
infection. However, in the HIV-positive/HPV18 group,
CD4 stromal staining showed to be decreased, when com-
pared with those in the HIV-negative/HPV18 group (P =
0.02) (Fig 1). Few koilocytotic cells presented CD8 stain-
ing. A significant decreasing of CD8 stromal staining was
observed when specimens with HPV16 infection aloneInfectious Agents and Cancer 2009, 4:11 http://www.infectagentscancer.com/content/4/1/11
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were compared with specimens without HPV16. How-
ever, CD8 stromal staining seemed to be increased in
specimens with both HIV and HPV16 infections, when
compared with specimens from patients HIV-negative/
HPV16 (P = 0.004) (Fig 2). CD8 stromal staining was
more frequently localised surrounding the metaplastic
epithelium and more intensively in specimens from HIV-
positive group, compared to the HIV-negative group (P =
0.001). In the HIV-positive/SIL group, clusters of lympho-
mononuclear cells were observed around vessels and adja-
cent to the basement membrane. HIV-positive/SIL group
exhibited a more intense CD8 stromal staining than
observed in the HIV-negative/SIL group (P  = 0.0005)
(Fig 3).
CD25 (IL-2Rα) and CD28 staining
In most specimens, CD25 staining was observed in basal
and immature epithelium, independent of HIV status (Fig
4). However, CD25 epithelial staining varied according to
both HPV status and lesion severity, being more frequent
in the HPV16-positive/HG-SIL group than in the HPV16-
negative/LG-SIL group (P = 0.03) (Fig 5). CD25 stromal
staining was primarily observed in lymphomononuclear
cells. More intense CD25 stromal staining was observed
in HPV16-negative/HG-SIL group than in the HPV16-neg-
ative/LG-SIL group (P = 0.002) (Fig 6). Both epithelial
and stromal CD25 staining (respectively, P = 0.02 and
0.005) were associated with HPV type infection (HPV16,
HPV16/18 and other HPV types), when compared to
HPV-negative group. No significant difference was found
Table 1: Data stratified by histopathological diagnosis, HIV status and HPV types.
HPV-
n(%)
HPV16
n(%)
HPV18
n(%)
HPV16/18
n(%)
HPVX
n(%)
Normal LG-SIL HG-SIL LG-SIL HG-SIL LG-SIL HG-SIL LG-SIL HG-SIL LG-SIL HG-SIL
HIV-negative (n = 47) 4 (8.5) 1(2.1) 3(6.4) 5(10.7) 10(21.3) 2(4.3) 6(12.8) 2(4.3) 6(12.8) 3(6.4) 5(10.7)
HIV-positive (n = 35) 5 (14.3) - - 4(11.4) 1(2.9) - 2(5.7) 1(2.9) 1(2.9) 16(45.7) 5(14.3)
Total (n = 82) 9(11.0) 1(1.2) 3(3.7) 9(11.0) 11(13.4) 2(2.4) 8(9.8) 3(3.7) 7(8.6) 19(23.2) 10(12.2)
HPV = Human papillomavirus; HIV = Human Immunodeficiency Virus; HPV X = Unidentified HPV types; LG-SIL = Low-grade Squamous 
Intraepithelial Lesion; HG-SIL = High-grade Squamous Intraepithelial Lesion.
Increased immunohistochemical expression of CD4 stromal staining of cervical specimens (mean ± SD) in the presence of  HPV18 infection (Kruskal-Wallis = 0.02) Figure 1
Increased immunohistochemical expression of CD4 stromal staining of cervical specimens (mean ± SD) in the 
presence of HPV18 infection (Kruskal-Wallis = 0.02). A = HPV-negative; B = HPV18-negative; C = HPV18-positive; D = 
both HIV and HPV are negative; E = both HIV and HPV18 are negative; F = HIV-negative, HPV18-positive; G = HIV-positive, 
HPV18-negative; H = both HIV and HPV18 are positive. HPV = Human papillomavirus; HIV = Human Immunodeficiency Virus.
A (n=8) B (n=35) C (n=18) D (n=3) E (n=22) F (n=15) G (n=13) H (n=3)
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                       Mean (± SD) CD4 stromal staining  Infectious Agents and Cancer 2009, 4:11 http://www.infectagentscancer.com/content/4/1/11
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Increasing immunohistochemical expression of CD8 stromal staining of cervical specimens (mean ± SD) in the presence of  HIV-infection (one way ANOVA test = 0.0005) Figure 3
Increasing immunohistochemical expression of CD8 stromal staining of cervical specimens (mean ± SD) in the 
presence of HIV-infection (one way ANOVA test = 0.0005). A = HIV-negative; B = HIV-positive; C = both HIV and SIL 
are negative; D = HIV-negative, SIL-positive; E = HIV-positive, SIL-negative; F = both HIV and SIL are positive; G = all HIV, SIL 
and HPV16 are positive. HPV = Human papillomavirus; HIV = Human Immunodeficiency Virus; SIL = Squamous Intraepithelial 
Lesion.
A (n=40) B (n=30) C (n=7) D (n=33) E (n=30) F (n=9) G (n=6)
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Reduced immunohistochemical expression of CD8 stromal staining of cervical specimens (mean ± SD) in the presence of  HPV16 infection (one way ANOVA test = 0.004) Figure 2
Reduced immunohistochemical expression of CD8 stromal staining of cervical specimens (mean ± SD) in the 
presence of HPV16 infection (one way ANOVA test = 0.004). A = HPV-negative; B = HPV16-negative; C = HPV16-
positive; D = both HIV and HPV are negative; E = both HIV and HPV16 are negative; F = HIV-negative, HPV16-positive; G = 
HIV-positive, HPV16-negative; H = both HIV and HPV16 are positive. HPV = Human papillomavirus; HIV = Human Immunode-
ficiency Virus.
A (n=11) B (n=33) C (n=26) D (n=3) E (n=14) F (n=22) G (n=19) H (n=5)
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CD25 staining in a basal and immature cervical squamous epithelium Figure 4
CD25 staining in a basal and immature cervical squamous epithelium.
Reduced immunohistochemical expression of CD25 epithelial staining of cervical specimens (mean ± SD) in the absence of  HPV16 infection (Kruskal-Wallis = 0.03) Figure 5
Reduced immunohistochemical expression of CD25 epithelial staining of cervical specimens (mean ± SD) in 
the absence of HPV16 infection (Kruskal-Wallis = 0.03). A = all HIV, HPV and SIL are negative; B = HPV16 total; C = 
HPV16-negative, LG-SIL-positive; D = both HPV16 and LG-SIL are positive; E = HPV16-negative, HG-SIL-positive; F = both 
HPV16 and HG-SIL are positive. HPV = Human papillomavirus; HIV = Human Immunodeficiency Virus; SIL = Squamous 
Intraepithelial Lesion; LG-SIL = Low-grade Squamous Intraepithelial Lesion; HG-SIL = High-grade Squamous Intraepithelial 
Lesion.
A (n=4) B (n=35) C (n=21) E (n=13) D (n=16) F (n=18)
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                     Mean (± SD) CD25 epithelial staining  Infectious Agents and Cancer 2009, 4:11 http://www.infectagentscancer.com/content/4/1/11
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in epithelial or stromal CD25 staining in patients present-
ing or not HG-SIL, regardless of HIV status.
CD28 stromal staining was observed in lymphomononu-
clear cells, particularly under the epithelial lesion and
under the transformation zone, sometimes as patchy
agglomerates, resembling germinative centres. CD28 epi-
thelial staining was less frequently observed in HIV-nega-
tive patients than in HIV-positive patients (P < 0.0001),
irrespective of the HPV type infection or the SIL severity
(Data not shown).
Positive correlations were observed between CD4 and
CD25 in stroma (r = 0.32, p = 0.01), CD4 and CD28 in
stroma (r = 0.33, p = 0.03) and between CD25 and CD28
both in epithelium (r = 0.31, p = 0.03) and in stroma (r =
0.40, p = 0.004).
Discussion
A cellular infiltration composed essentially of CD4 and
macrophages is frequently observed in condyloma under
spontaneous regression [23], and a decrease in the
number of Langerhans cells in the transformation zone
has been associated with a reduced in vitro T cell prolifer-
ation and IL-2 production [24]. With the progression to
HG-SIL, the number of immature Langerhans cells
increase with a consequent deficient function [24,25]. In
this study, we evaluated the intensity and distribution of
CD4, CD8, CD25 and CD28 molecules in cervical speci-
mens with SIL, stratified according to HIV status and HPV
type.
In the present study, specimens harbouring HPV18
showed a decreased CD4 stromal staining and HPV16
infection was associated with an increased CD8 stromal
staining, in HIV-infected women. Since CD8 cells are
recruited preferentially to cervical lesions with progres-
sion to invasion [26], and in regressing CIN1 lesions,
CD4+ cells predominated within the stroma with highest
CD4/CD8 ratio compared with progressive CIN1 [27-29],
these findings may explain the progression or regression
of the HPV infection towards carcinogenesis, particullarly
among HIV-infected women.
HPV16 is considered to be the major etiologic agent of
squamous cervical carcinoma and keratinocytes (non-
professional antigen presenting cells) are reported to
directly present viral antigens to cytotoxic T lymphocytes
by cross priming [1], whereas HPV18 is more frequently
associated with adenocarcinoma. The mechanisms of
viral peptide presentation are less studied than those
reported for squamous carcinoma. Increased HPV16 E7-
specific T helper cell responses are associated with persist-
ent HPV16 infection, HG-SIL and invasive cervical carci-
noma [30]. It is accepted that HPV infects keratinocytes
and interferes with the local cytokine expression [31-33],
but it is still unknown how HPV together with HIV influ-
ences local T cell function.
Reduced immunohistochemical expression of CD25 stromal staining of cervical specimens (mean ± SD) in the absence of  HPV16 infection (Kruskal-Wallis = 0.002) Figure 6
Reduced immunohistochemical expression of CD25 stromal staining of cervical specimens (mean ± SD) in the 
absence of HPV16 infection (Kruskal-Wallis = 0.002). A = all HIV, HPV and SIL are negative; B = HPV16 total; C = 
HPV16-negative, LG-SIL-positive; D = HPV16-negative, HG-SIL-positive; E = both HPV16 and LG-SIL are positive; F = both 
HPV16 and HG-SIL are positive. HPV = Human papillomavirus; HIV = Human Immunodeficiency Virus; SIL = Squamous 
Intraepithelial Lesion; LG-SIL = Low-grade Squamous Intraepithelial Lesion; HG-SIL = High-grade Squamous Intraepithelial 
Lesion.
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In this study, CD8 staining increased in HIV infected
group and further increased with concomitant SIL. In
addition, both the epithelium and stroma of the HIV+/SIL
group presented an increased expression of CD8 com-
pared to the HIV-/SIL group. These findings indicate a
continuous stimulation by persistent HPV infection, in
agreement with other authors [27,28]. Because of the
proximity of the columnar epithelium to the stroma and
the lack of keratinocytes in the endocervix, the findings of
this study suggest that stromal lymphomononuclear CD4
cells (T CD4 and macrophages) may cope better than CD8
in HPV18 infection. In other words, macrophages may be
the major APC in stroma and CD4 cells (T lymphocytes
and macrophages) may be involved in immunity against
HPV18.
Several studies have shown that peripheral blood lym-
phocytes produce IL-2[34,35] and generate cytotoxic
activity [36] after specific HPV16 E7 protein stimulation.
De Gruijl et al. [37] reported an increased IL-2 production
by peripheral blood CD4+ T cells, associated with persist-
ent HPV infection and progression of a premalignant
lesion and a higher production of Th2 cytokines related to
cervical malignancy. In our study, HPV16 associated with
decreased stromal CD8 and CD25 expression and
increased CD25 staining was observed in both epithelium
and stroma with HG-SIL. The expression of IL-2R on
keratinocytes and the IL-2 secretion has been reported in
different phases of cancer cell development [38,39]. Bind-
ing of IL-2 to IL-2R on tumour cells may down-regulate
surface expression of IL-2R, the intercellular adhesion
molecule-I (ICAM-I) and the MHC class I antigens and
may inhibit the in vitro growth of tumour cells by arresting
these cells in the G0/G1 cell cycle [40]. Although intrale-
sional IL-2 levels were not measured in the present study,
the increased expression of CD25 on epithelial cells sug-
gests that IL-2 may control tumour progression.
In this study, irrespective of HPV type and HIV status, sig-
nificant positive correlations were observed between
CD4/CD28 and CD4/CD25 in stroma and between
CD25/CD28 in stroma and epithelium of SIL specimens,
indicating that CD4 cells are activated, i.e., expressing co-
stimulatory molecule (CD28) and responding to IL-2 by
expressing CD25. Since IL-2 reportedly induces lym-
phocyte proliferation/apoptosis depending on IL-2 pro-
duction and the persistence of the immune response [13],
one may hypothesise that lesions able to regress contain
more activated CD4 cells, CD28 and CD25 [2]. In con-
trast, in malignant lesions, tumour-infiltrating lym-
phocytes are reported to be functionally inhibited, losing
their ability of clonal proliferation due to the depression
of CD25 [9]. Since less than 2% of CD4/CD8 cells express-
ing CD25 molecule is observed in the normal endocervix
[41] and since CD4/CD25 cells are recognised as regula-
tory T cells [13], the role of these cells in SIL development
should be further evaluated performing longitudinal stud-
ies double staining CD4 and CD25.
In conclusion, our results indicate that HPV type and HIV
status may influence lymphomononuclear cell marker
staining in cervical lesions. A particular immune response
may be triggered depending on the balance of these varia-
bles, culminating in the progression to cancer. Knowledge
of the lymphomonuclear cell profile and the tumour
immunogen may help understanding HPV evasion mech-
anisms and enable new proposals of anti-tumoral treat-
ment, especially therapeutic vaccines against cervical
lesions.
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